vascular endothelial growth factors

Summary

Summary: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.

Top Publications

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
  3. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  4. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
  5. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
  6. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
  7. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
  8. ncbi Vascular endothelial growth factors and angiogenesis in eye disease
    A N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands
    Prog Retin Eye Res 22:1-29. 2003
  9. ncbi Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
    B Barleon
    Institute of Molecular Medicine, Tumor Biology Center Freiburg, Germany
    Blood 87:3336-43. 1996
  10. ncbi Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
    G H Fong
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nature 376:66-70. 1995

Research Grants

  1. Fetal HCMV Infection: Role of the Human Placenta
    LENORE PALMA PEREIRA; Fiscal Year: 2013
  2. Role of Angiogenesis in Distraction Osteogenesis
    LOUIS CHARLES GERSTENFELD; Fiscal Year: 2013
  3. Lymphotoxin: Regulation and Biologic Function
    NANCY RUDDLE; Fiscal Year: 2009
  4. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas E Vlahakis; Fiscal Year: 2010
  5. A Novel Treatment for Retinal Ischemia
    Mark S Humayun; Fiscal Year: 2013
  6. Role of Neuropilin receptors in lymphangiogenesis
    ANNE CHRISTINE EICHMANN; Fiscal Year: 2013
  7. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce J Herron; Fiscal Year: 2010
  8. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2012
  9. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
  10. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004

Detail Information

Publications283 found, 100 shown here

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
    ....
  3. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  4. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
    ....
  5. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  6. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
    ....
  7. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    ..It may also become an important target for cancer therapy...
  8. ncbi Vascular endothelial growth factors and angiogenesis in eye disease
    A N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands
    Prog Retin Eye Res 22:1-29. 2003
    ..On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD...
  9. ncbi Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
    B Barleon
    Institute of Molecular Medicine, Tumor Biology Center Freiburg, Germany
    Blood 87:3336-43. 1996
    ..The results presented here suggest that monocyte chemotaxis in response to VEGF and most likely to PlGF152 is mediated by flt-1 and thus show a possible function for the VEGF-receptor flt-1...
  10. ncbi Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
    G H Fong
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nature 376:66-70. 1995
    ..We suggest that the Flt-1 signalling pathway may regulate normal endothelial cell-cell or cell-matrix interactions during vascular development...
  11. ncbi Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    G Thurston
    Department of Anatomy and Cardiovascular Research Institute, University of California, San Francisco, CA 94143 0452, USA
    Science 286:2511-4. 1999
    ..Ang1 therefore may be useful for reducing microvascular leakage in diseases in which the leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels...
  12. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  13. ncbi The biology of vascular endothelial growth factors
    Tuomas Tammela
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, University of Helsinki, 00014 Helsinki, Finland
    Cardiovasc Res 65:550-63. 2005
    ..In this review, we will discuss recent advances in angiogenesis research and provide an overview of the molecular players involved in lymphangiogenesis...
  14. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  15. pmc Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
    S Hiratsuka
    Department of Genetics, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Proc Natl Acad Sci U S A 95:9349-54. 1998
    ..These results indicate that Flt-1 without tyrosine kinase domain is sufficient to allow embryonic development with normal angiogenesis, and that a receptor tyrosine kinase plays a main biological role as a ligand-binding molecule...
  16. ncbi Vascular endothelial growth factor is a secreted angiogenic mitogen
    D W Leung
    Department of Molecular Biology, Genetech, South San Francisco, CA 94080
    Science 246:1306-9. 1989
    ..Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF...
  17. pmc Vascular endothelial growth factors and vascular permeability
    David O Bates
    Microvascular Research Laboratories, Department of Physiology and Pharmacology, School of Veterinary Sciences, Bristol Heart Institute, University of Bristol, Southwell Street, Bristol, UK
    Cardiovasc Res 87:262-71. 2010
    b>Vascular endothelial growth factors (VEGFs) are key regulators of permeability. The principal evidence behind how they increase vascular permeability in vivo and in vitro and the consequences of that increase are addressed here...
  18. ncbi A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels
    W Renner
    Department of Internal Medicine, Division of Angiology, Karl Franzens University Graz, Graz, Austria
    J Vasc Res 37:443-8. 2000
    ..Aim of the present study was to search for mutations in the 3' untranslated region (3'-UTR) of the VEGF gene and to analyze their relation to VEGF plasma levels...
  19. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued...
  20. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  21. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
    ..Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis...
  22. ncbi Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells
    I Kim
    National Creative Research Initiatives Center for Cardiac Regeneration, and the Department of Urology, Chonbuk National University School of Medicine, Chonju, 560-180, Republic of Korea
    J Biol Chem 276:7614-20. 2001
    ..The existence of parallel inverse signaling implies that the induction of adhesion molecule expression by VEGF is very finely regulated...
  23. ncbi Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics
    H Zhong
    The Johns Hopkins Oncology Center, Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 60:1541-5. 2000
    ..These data indicate that pharmacological agents that target PI3K, AKT, or FRAP in tumor cells inhibit HIF-1alpha expression and that such inhibition may contribute to therapeutic efficacy...
  24. ncbi Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
    B Oosthuyse
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, B 3000, Belgium
    Nat Genet 28:131-8. 2001
    ..Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons...
  25. ncbi Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
    R Bos
    Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Natl Cancer Inst 93:309-14. 2001
    ..Increased levels of HIF-1 alpha are associated with increased proliferation and increased expression of ER and VEGF. Thus, increased levels of HIF-1 alpha are potentially associated with more aggressive tumors...
  26. ncbi VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding
    Shay Soker
    Department of Urology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Biochem 85:357-68. 2002
    ..These complexes are formed on the surface of EC and in a juxtacrine manner via association of tumor cell NRP1 and EC KDR...
  27. pmc Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development
    Chenghua Gu
    Department of Neuroscience, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
    Dev Cell 5:45-57. 2003
    ..multiple ligands from structurally distinct families, including secreted semaphorins (Sema) and vascular endothelial growth factors (VEGF)...
  28. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  29. ncbi How do angiopoietins Tie in with vascular endothelial growth factors?
    Pipsa Saharinen
    Molecular and Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Finland
    Curr Opin Hematol 17:198-205. 2010
    ....
  30. ncbi Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer
    Sònia Tugues
    Uppsala University, Dept of Immunology, Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjoldsv 20, 751 85 Uppsala, Sweden
    Mol Aspects Med 32:88-111. 2011
    b>Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases...
  31. pmc Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    J A Forsythe
    Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, USA
    Mol Cell Biol 16:4604-13. 1996
    ..VEGF mRNA was not induced by hypoxia in mutant cells that do not express the HIF-1beta (ARNT) subunit. These findings implicate HIF-1 in the activation of VEGF transcription in hypoxic cells...
  32. pmc VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain
    N van Bruggen
    Department of Neuroscience, Genentech Inc, South San Francisco, California 94080, USA
    J Clin Invest 104:1613-20. 1999
    ..These results demonstrate that antagonism of VEGF reduces ischemia/reperfusion-related brain edema and injury, implicating VEGF in the pathogenesis of stroke and related disorders...
  33. ncbi Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nat Med 5:495-502. 1999
  34. ncbi Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry
    Takahisa Iwata
    Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan
    Urology 71:749-54. 2008
    Lymphangiogenesis is associated with tumor progression in various cancers and is regulated by vascular endothelial growth factors (VEGFs)...
  35. pmc Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
    Ingeborg Stalmans
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
    J Clin Invest 109:327-36. 2002
    ..These findings reveal distinct roles of the various VEGF isoforms in vascular patterning and arterial development in the retina...
  36. ncbi Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor
    M Sondell
    Department of Animal Physiology, Lund University, Helgonav 3 B, S 223 62, Lund, Sweden
    Eur J Neurosci 12:4243-54. 2000
    ..The results strongly suggest that VEGF acts as a neurotrophic factor and plays an important role during the regeneration of peripheral nerves...
  37. ncbi Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
    R J Kaner
    Division of Pulmonary and Critical Care Medicine and Weill Medical College of Cornell University, New York, New York, USA
    Am J Respir Cell Mol Biol 22:657-64. 2000
    ..Together, these data suggest that overexpression of VEGF in the lung may be one mechanism of increased pulmonary vascular permeability in the early stages of acute lung injury...
  38. ncbi Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation
    M M Deckers
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    Endocrinology 141:1667-74. 2000
    ..The expression pattern of VEGFs and their receptors shown here suggests that VEGFs play an important role in the regulation of bone remodeling by attracting endothelial cells and osteoclasts and by stimulating osteoblast differentiation...
  39. ncbi The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
    D T Shima
    Program in Biological and Biomedical Sciences and the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 271:3877-83. 1996
    ..These data and reagents will allow the molecular and genetic analysis of mechanisms that control the developmental and pathological expression of VEGF...
  40. ncbi Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
    S Ugurel
    Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany
    J Clin Oncol 19:577-83. 2001
    ..CONCLUSION: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients...
  41. ncbi The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA
    K A Houck
    Department of Molecular Biology, Genetech, Inc, South San Francisco, California 94080
    Mol Endocrinol 5:1806-14. 1991
    ..Thus, alternative splicing of VEGF RNA can produce four polypeptides with strikingly different secretion patterns, which suggests multiple physiological roles for this family of proteins...
  42. ncbi p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
    B Linderholm
    Department of Oncology, Umea University, Sweden
    Int J Cancer 89:51-62. 2000
    ..Combination of these 2 biological markers appears to give additional predictive information of survival. A high-risk group of patients was associated with p53 positivity and higher VEGF content...
  43. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
    ..Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium...
  44. ncbi Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression
    T Sanchez-Elsner
    Centro de Investigaciones Biologicas, CSIC, Velazquez 144, 28006 Madrid, Spain
    J Biol Chem 276:38527-35. 2001
    ..These results demonstrate that both TGF-beta and hypoxia signaling pathways can synergize in the regulation of VEGF gene expression at the transcriptional level...
  45. ncbi Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
    S Molica
    Divisione Ematologia e Oncologia Clinica, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro
    Br J Haematol 107:605-10. 1999
    ..We conclude that increased serum levels of VEGF can be considered useful for predicting the risk of DP and add prognostic information to the Rai subclassification of stage A CLL...
  46. ncbi Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
    L E Smith
    Department of Ophthalmology, Harvard Medical School and Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nat Med 5:1390-5. 1999
    ..They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy...
  47. ncbi Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain
    J M Krum
    Department of Anatomy and Cell Biology, The George Washington University Medical Center, Washington, DC 20037, USA
    Neuroscience 110:589-604. 2002
    ..From these results we suggest that administered VEGF has heretofore unanticipated pleiotrophic effects in the adult CNS...
  48. ncbi Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
    J Adams
    Imperial Cancer Research Fund Cancer Medicine Research Unit, St James s University Hospital, Leeds, United Kingdom
    Cancer Res 60:2898-905. 2000
    ..MVD correlated with tumor size. Tamoxifen-induced increases in VEGF may be important in clinical prognosis or associated pathologies...
  49. ncbi Regulation of vascular permeability by vascular endothelial growth factors
    D O Bates
    Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK
    Vascul Pharmacol 39:225-37. 2002
    ..This review will outline the mechanisms by which VEGFs do this and discuss some of the difficulties in interpreting data from VEGF studies due to the conflicting and synergistic effects of these actions...
  50. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
    ..This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression...
  51. ncbi The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
    B K Linderholm
    Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden
    Cancer Res 61:2256-60. 2001
    ..4 and 2.1 for BCCS and RFS, respectively. VEGF expression is related to p53 status in human breast cancer patients. Combining VEGF with p53 status resulted in better prognostic prediction...
  52. ncbi Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis
    G Christofori
    Department of Biochemistry and Biophysics, University of California, San Francisco 94143 0534, USA
    Mol Endocrinol 9:1760-70. 1995
    ..While VEGF may also play an important role in the growth of new blood vessels during islet cell tumorigenesis, it cannot be the only factor required for the activation of tumor angiogenesis...
  53. ncbi Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
    N W Gale
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591 6707, USA
    Genes Dev 13:1055-66. 1999
  54. ncbi Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine
    Seppo Yla-Herttuala
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute, Kuopio University, Kuopio, Finland
    J Am Coll Cardiol 49:1015-26. 2007
    ..Here, we review the biology and effects of VEGFs as well as the current status of clinical applications and future perspectives of the therapeutic use of VEGFs in cardiovascular medicine...
  55. ncbi Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    D I Gabrilovich
    Department of Medicine and The Vanderbilt Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6838, USA
    Clin Cancer Res 5:2963-70. 1999
    ..This effect was associated with the induction of significant anti-p53 CTL responses only in this group of mice. These data suggest that inhibition of VEGF may be a valuable adjuvant in the immunotherapy of cancer...
  56. ncbi Vascular endothelial growth factor and vascular targeting of solid tumors
    R A Brekken
    The Hope Heart Institute, Department of Vascular Biology, Seattle, WA 98104 2046, USA
    Anticancer Res 21:4221-9. 2001
    ..We conclude that 2C3 might have dual activity as an anti-angiogenic agent by inhibiting VEGFR2 activity and as a vascular targeting agent for selective drug delivery to tumor vessels...
  57. ncbi Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro
    G Balconi
    Istituto di Ricerche Farmacologiche Mario Negri G B, R S, E D, Milan, Italy
    Arterioscler Thromb Vasc Biol 20:1443-51. 2000
    ..We propose that this approach may be useful for obtaining endothelial cells carrying gene mutations that are lethal at very early stages of development...
  58. pmc VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm
    Lynda Erskine
    School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK
    Neuron 70:951-65. 2011
    ..These findings have identified a permissive midline signal for axons at the chiasm midline and provide in vivo evidence that VEGF-A is an essential axon guidance cue...
  59. ncbi The role of VEGF in normal and neoplastic hematopoiesis
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 81:20-31. 2003
    ....
  60. ncbi The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1
    G Fuh
    Department of Protein Engineering, Genentech Inc, South San Francisco, California 94080, USA
    J Biol Chem 275:26690-5. 2000
    ..Furthermore, Flt-1 may function as a negative regulator of angiogenesis by competing for NP-1...
  61. ncbi VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation
    S Kanazawa
    Department of Surgery, Himeji Central Hospital, Japan
    Am J Gastroenterol 96:822-8. 2001
    ..CONCLUSIONS: It is suggested that the reciprocal reaction of these cytokines may contribute to angiogenesis in IBD b inducing intestinal ischemia through vasoconstriction...
  62. ncbi Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor
    D Bagnard
    , Neurobiologie Experimentale et Physiopathologie, , 69372 Lyon Cedex 08, France
    J Neurosci 21:3332-41. 2001
    ..These results indicate that the balance between guidance molecules and angiogenic factors can modulate the migration, apoptosis (or survival), and proliferation of neural progenitor cells through shared receptors...
  63. ncbi Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis
    R Bagheri-Yarmand
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 275:39451-7. 2000
    ..These results suggest that heregulin-beta1 regulates angiogenesis via up-regulation of VEGF expression and that Pak1 plays an important role in controlling VEGF expression and, consequently, VEGF secretion and function...
  64. ncbi The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts
    T Takahashi
    Department of Genetics, Institute of Medical Science, University of Tokyo, Minato ku, Japan
    Oncogene 14:2079-89. 1997
    ..These results suggest that the KDR/Flk-1 utilizes cell type-specific signal transduction pathway(s) for MAP kinase activation and the mitotic response in endothelial cells...
  65. pmc Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    R L Kendall
    Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065
    Proc Natl Acad Sci U S A 90:10705-9. 1993
    ....
  66. ncbi Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival
    A Obermair
    Department of Gynecology and Obstetrics University Hospital of Vienna, Austria
    Int J Cancer 74:455-8. 1997
    ....
  67. ncbi Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
    L Hlatky
    Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts 02115
    Cancer Res 54:6083-6. 1994
    ..Thus, mammary stromal cells, only recently considered in the regulation of breast carcinomas, may play a hitherto unrealized role in breast cancer angiogenesis...
  68. pmc Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo
    Kunlin Jin
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Proc Natl Acad Sci U S A 99:11946-50. 2002
    ..Cells labeled with BrdUrd after VEGF treatment in vivo include immature and mature neurons, astroglia, and endothelial cells. These findings implicate the angiogenesis factor VEGF in neurogenesis as well...
  69. ncbi Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth
    H E Ryan
    Department of Biology, University of California, San Diego 92093 0366, USA
    Cancer Res 60:4010-5. 2000
    ..The evidence from these experiments indicates that hypoxic response via HIF-1alpha is an important positive factor in solid tumor growth and that HIF-1alpha affects tumor expansion in ways unrelated to its regulation of VEGF expression...
  70. ncbi Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    C Suri
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Cell 87:1171-80. 1996
    ..Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme...
  71. ncbi Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
    M Kaya
    Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan
    Clin Cancer Res 6:572-7. 2000
    ....
  72. pmc Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology
    R E Banks
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds UK
    Br J Cancer 77:956-64. 1998
    ..e.g. wound healing, and in tumour metastasis, when platelets adhering to circulating tumour cells may release VEGF at points of adhesion to endothelium, leading to hyperpermeability and extravasation of cells...
  73. pmc The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease
    G P Pidgeon
    Royal College of Surgeons in Ireland, Department of Surgery, Beaumont Hospital, Dublin, Ireland
    Br J Cancer 81:1311-7. 1999
    ..These data indicate that endotoxin introduced during surgery is associated with the enhanced growth of metastases following surgical trauma, by altering the critical balances governing cellular growth and angiogenesis...
  74. ncbi Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer
    C M Lennard
    Departments of Otolaryngology, Clinical Investigation and Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 129:552-8. 2001
    ..007). CONCLUSIONS: These data demonstrate that the immunohistochemical pattern of VEGF staining in the initial surgical specimen is strongly associated with the incidence of local and distant metastasis in papillary thyroid cancer...
  75. pmc VEGF-Trap: a VEGF blocker with potent antitumor effects
    Jocelyn Holash
    Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 99:11393-8. 2002
    ..VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor...
  76. pmc Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148
    Maria Grazia Lampugnani
    FIRC Institute of Molecular Oncology, 20139 Milan, Italy
    J Cell Biol 161:793-804. 2003
    ..In sparse cells or in VE-cadherin-null cells, this phenomenon cannot occur and the receptor is fully activated by the growth factor...
  77. ncbi Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
    S Soker
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 92:735-45. 1998
    ..We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis...
  78. pmc Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
    D Maglione
    International Institute of Genetics and Biophysics, Consiglio Nazionale della Ricerce, Naples, Italy
    Proc Natl Acad Sci U S A 88:9267-71. 1991
    ..In addition, PlGF, like VPF, proves to be a dimeric protein. Finally, a conditioned medium from COS-1 cells containing PlGF is capable of stimulating specifically the growth of CPA, a line of endothelial cells, in vitro...
  79. ncbi Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo
    D Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 61:6020-4. 2001
    ..These results suggest that VEGF transcription in brain tumors is regulated by both tissue pO(2) and pH via distinct pathways...
  80. pmc Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2
    Francescopaolo Granata
    Division of Clinical Immunology and Allergy and Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples
    J Immunol 184:5232-41. 2010
    Angiogenesis and lymphangiogenesis mediated by vascular endothelial growth factors (VEGFs) are main features of chronic inflammation and tumors...
  81. ncbi Covalently conjugated VEGF--fibrin matrices for endothelialization
    A H Zisch
    Department of Materials and Institute for Biomedical Engineering, ETH and University of Zurich, Moussonstrasse 18, 8044 Zurich, Switzerland
    J Control Release 72:101-13. 2001
    ..When used as a ingrowth matrix, such VEGF incorporating materials could be useful in a variety of clinical situations that require an angiogenic response into an ischemic region or inplant...
  82. ncbi Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    Markus Guba
    Department of Surgery, University of Regensburg, Regensburg, Germany
    Nat Med 8:128-35. 2002
    ..Thus, the use of RAPA, instead of cyclosporine, may reduce the chance of recurrent or de novo cancer in high-risk transplant patients...
  83. pmc Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma
    Z von Marschall
    Department of Hepatology and Gastroenterology, Charite, Campus Virchow Klinikum, Humboldt University, Augustenburger Platz 1, 13353 Berlin, Germany
    Gut 48:87-96. 2001
    ..In the current study we analysed expression of VEGF and its receptors in human hepatocellular carcinoma (HCC) and investigated the molecular mechanisms of VEGF regulation by hypoxia...
  84. ncbi Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival
    Edwin P Hui
    Departments of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Clin Cancer Res 8:2595-604. 2002
    ....
  85. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  86. ncbi Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
    P C Maisonpierre
    Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 277:55-60. 1997
    ..Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system...
  87. ncbi Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation
    Helen Hutchings
    GDR CNRS 1927 Angiogenese and UMR CNRS 5089, Institut de Pharmacologie et Biologie Structurale, Toulouse, France
    FASEB J 17:1520-2. 2003
    ..We have thus determined a new VEGF receptor-independent role for immobilized VEGF in supporting cell adhesion and survival through interactions with integrins...
  88. ncbi Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion
    Shelley R Boyd
    Moorfields Eye Hospital, City Road, London EC1V 2PD, England
    Arch Ophthalmol 120:1644-50. 2002
    ..To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion...
  89. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
    ..These results suggest that further exploration of SU11248 activity in AML patients is warranted...
  90. ncbi Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 394:485-90. 1998
    ..As hypoxic stress contributes to many (patho)biological disorders, this new role for HIF-1alpha in hypoxic control of cell growth and death may be of general pathophysiological importance...
  91. ncbi Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
    A Pettersson
    Department of Pathology, Children s Hospital, and Harvard Institute of Human Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA
    Lab Invest 80:99-115. 2000
    ..Finally, the muscular vessels that developed from mother vessels in skin and perimuscle fat have the structure of collaterals and could be useful clinically in the relief of tissue ischemia...
  92. ncbi Blood vessels and nerves: common signals, pathways and diseases
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Rev Genet 4:710-20. 2003
    ..The realization that both systems use common genetic pathways should not only form links between vascular biology and neuroscience, but also promises to accelerate the discovery of new mechanistic insights and therapeutic opportunities...
  93. ncbi The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:7788-95. 1996
    ..The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity...
  94. ncbi Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease
    Ferdinando Carlo Sasso
    Department of Geriatrics and Metabolic Disease, Second University of Naples, Naples, Italy
    J Am Coll Cardiol 46:827-34. 2005
    ..The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD)...
  95. ncbi VEGF receptor signalling - in control of vascular function
    Anna Karin Olsson
    Department of Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjöldv 20, 751 85 Uppsala, Sweden
    Nat Rev Mol Cell Biol 7:359-71. 2006
    ..Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease...
  96. pmc Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4
    J Lee
    Department of Molecular Biology, Genetech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 93:1988-92. 1996
    ..A 2.4-kb VRP mRNA is found in several human tissues including adult heart, placenta, ovary, and small intestine and in fetal lung and kidney...
  97. ncbi Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody
    F Tanaka
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan
    Clin Cancer Res 7:3410-5. 2001
    ..029), whereas CD34-IMVD was not (P = 0.070). CONCLUSIONS: Anti-CD105 mAb proved to be superior to anti-CD34 mAb in evaluation of angiogenesis in NSCLC...
  98. ncbi Vascular growth factors and lymphangiogenesis
    Lotta Jussila
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, and Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Finland
    Physiol Rev 82:673-700. 2002
    ..Discoveries made so far will be helpful in the diagnosis of certain vascular tumors, in the design of specific treatments for lymphedema, and in the prevention of metastatic tumor spread via the lymphatic system...
  99. ncbi Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration
    Hideki Iwaguro
    Division of Cardiovascular Research and Medicine, St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA
    Circulation 105:732-8. 2002
    ..In the current study, we investigated the hypothesis that gene transfer can be used to achieve phenotypic modulation of EPCs...
  100. ncbi Molecular and functional diversity of vascular endothelial growth factors
    Yasuo Yamazaki
    Department of Biochemistry, Meiji Pharmaceutical University, 2 522 1 Noshio, Kiyose, Tokyo, Japan
    Mol Divers 10:515-27. 2006
    ..This review will highlight the molecular and functional diversity of VEGF family proteins...
  101. ncbi Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1
    Young Mi Kim
    Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chunchon, Kangwon Do 200 701, Korea
    J Biol Chem 277:27872-9. 2002
    ..Our findings suggest that a direct interaction of endostatin with KDR/Flk-1 may be involved in the inhibitory function of endostatin toward VEGF actions and responsible for its potent anti-angiogenic and anti-tumor activities in vivo...

Research Grants66

  1. Fetal HCMV Infection: Role of the Human Placenta
    LENORE PALMA PEREIRA; Fiscal Year: 2013
    ..b>Vascular endothelial growth factors A and C (VEGF-A/C) upregulated in infected CTB could have paracrine effects on LEC functions in ..
  2. Role of Angiogenesis in Distraction Osteogenesis
    LOUIS CHARLES GERSTENFELD; Fiscal Year: 2013
    ..The completion of Aims 1 and 2 will determine if ECs are a primary cell source of BMP2 in regulating skeletal healing after surgery or injury and if BMP2 has a functional role in vasculogenesis. ..
  3. Lymphotoxin: Regulation and Biologic Function
    NANCY RUDDLE; Fiscal Year: 2009
    ..abstract_text> ..
  4. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas E Vlahakis; Fiscal Year: 2010
    ..This KO8 program will support investigations into the role of alpha9-beta1 integrin and vascular endothelial growth factors (VEGF) C and D in pulmonary lymphatic development and function...
  5. A Novel Treatment for Retinal Ischemia
    Mark S Humayun; Fiscal Year: 2013
    ..Moreover, even with intravitreal injections of anti-Vascular Endothelial Growth Factors, or laser, in approximately 50% of patients, vision does not improve...
  6. Role of Neuropilin receptors in lymphangiogenesis
    ANNE CHRISTINE EICHMANN; Fiscal Year: 2013
    ..We will investigate the role of Neuropilin 1 and 2 (Nrp1, 2), co-receptors for vascular endothelial growth factors (VEGFs) and class III Semaphorins (Sema3), in lymphangiogenesis...
  7. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce J Herron; Fiscal Year: 2010
    ..The Vascular Endothelial Growth Factors (VEGF) are a family of secreted glycoproteins that control angiogenesis...
  8. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2012
    ..This application is focused on understanding the mechanisms that these factors use to induce lymphangiogenesis and metastasis in melanoma, as well as how these mechanisms impact emerging cancer therapies. ..
  9. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  10. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004
    ..Bronchoalveolar lavage and plasma levels of VEGF will be measured in patients with acute lung injury to develop the hypothesis that overexpression of VEGF in lung may be one mechanism favoring increased permeability. ..
  11. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
    ..Our model will provide a useful tool to directly examine the roles of various factors in retinal vascular diseases in a setting that maintains normal tissue architecture. ..
  12. Augmentation of Lymphangiogenesis by Increased Fluid Channeling in Mouse Skin
    Jeremy Goldman; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Vascular endothelial growth factors (VEGF)-C and -D have been shown to be necessary for lymphatic proliferation and migration during lymphangiogenesis by binding VEGFR-3 on lymphatic ..
  13. THE MAJOR ANGIOGENIC FACTORS IN PLACENTAL ANGIOGENESIS
    Lawrence Reynolds; Fiscal Year: 2004
    ..Recent studies, including those in gene-knockout mice, indicate that vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), and angiopoietins (ANG) play major roles in the ..
  14. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2006
    ..abstract_text> ..
  15. Genetic Control of Cranial Neural Crest Migration
    Hung Hsiang Yu; Fiscal Year: 2005
    ..of neuropilin 2 (Npn-2), a binding receptor for class 3 secreted semaphorin 3C and 3F and vascular endothelial growth factors in vertebrates...
  16. REGULATION OF ANGIOGENESIS BY HUMAN HERPESVIRUS 8
    Sankar Swaminathan; Fiscal Year: 2000
    ..Growth of HHV8-infected endothelial cells is correlated with increased expression of vascular endothelial growth factors (VEGFs) and VEGF receptors...
  17. NF-KAPPA BS IN VIVO ROLE IN DERMATITIS AND ANGIOGENESIS
    JOHN KLEMENT; Fiscal Year: 1999
    ..Specifically, the expression of vascular endothelial growth factors and their targets will be investigated in terms of the temporal and spatial pattern of expression...
  18. GLIAL MEDIATORS OF CNS ISCHEMIC INJURY
    MARTHA DOWNEN; Fiscal Year: 2000
    ..The induction of growth factors i.e. vascular endothelial growth factors (VEGF) following hypoxia is purported to be part of the cascade of stroke induced injury...
  19. Angiogenesis:Novel Basic Science Insight & Human Therapy
    Napoleone Ferrara; Fiscal Year: 2004
    ..abstract_text> ..
  20. ANGIOGENIC THERAPY FOR INFARCTED AND ISCHEMIC HEART
    Robert Tomanek; Fiscal Year: 2003
    ..Such interventions have a number of advantages over more invasive interventions, e.g., the delivery of oxogenous growth factors or gene therapy. ..
  21. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007
    ..In Phase II we will develop LFn-liposomes with combination of LF and EF inhibitors, validate these liposomes in animal models of anthrax infection, and pre-clinical steps required for IND filing. [unreadable] [unreadable] [unreadable]..
  22. Regulation of Coronary Vessel Assembly and Growth
    Robert Tomanek; Fiscal Year: 2007
    ..Since cardiac development depends on timely and adequate vascularization, an understanding of coronary vasculogenesis and angiogenesis will provide an important foundation for our understanding of cardiac defects. ..
  23. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer
    Marina Backer; Fiscal Year: 2008
    ..We expect that this data establish feasibility of clinical development for EGF-SLiP. [unreadable] [unreadable] [unreadable]..
  24. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  25. Hypoxia-Inducible Factor 1 and Oxygen Homeostasis
    Gregg Semenza; Fiscal Year: 2009
    ....
  26. EXPRESSION OF HUMAN ERYTHROPOIETIN GENE
    Gregg Semenza; Fiscal Year: 2002
    ..abstract_text> ..
  27. Mechanism of Myocardial Angiogenesis in Transgenic/Knockout Animals
    Nilanjana Maulik; Fiscal Year: 2010
    ..This proposal will provide and will identify important new insights into the cellular and molecular mechanisms of the cardioprotection provided by VEGF signaling through important candidate genes. ..
  28. Function of VEGF Receptor-1 on Colorectal Cancer Cells
    Lee Ellis; Fiscal Year: 2009
    ..In addition, it is possible that VEGFR-1 expression on CRC cells may serve as a "predictive factor" for anti-VEGF/receptor containing anti-neoplastic regimens. ..
  29. Role of VEGF in Neonatal Pulmonary Hypertension
    Theresa Grover; Fiscal Year: 2008
    ..These studies will provide an integrated approach to the hypothesis, incorporating whole animal physiology coupled with molecular and cellular studies. ..
  30. Image-Guided Pro-Drug/Enzyme Therapy
    Zaver Bhujwalla; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  31. Molecular Classification and Therapy of CNS Lymphomas
    James Rubenstein; Fiscal Year: 2008
    ..We will perform gene expression profile analysis of these tumors from diagnostic specimens obtained from a frozen tumor bank to identify a set of genes, which can be used to predict outcome. ..
  32. Imaging Lymphatic Clearance in Tumor Metastasis
    Zaver Bhujwalla; Fiscal Year: 2003
    ..abstract_text> ..
  33. Development of SL-101, An Immunotoxin that Targets Cancer Stem Cells
    Malcolm Moore; Fiscal Year: 2006
    ..This Phase I STTR grant will cover the development of SL-101 through key phases of pre-clinical development. [unreadable] [unreadable] [unreadable]..
  34. MAMMARY TUMOR CHEMOPREVENTION BY ANGIOGENIC INHIBITORS
    Sue Heffelfinger; Fiscal Year: 2003
    ..In addition, this study presents a non-hormonal approach to the problem of chemoprophylaxis in high-risk women. ..
  35. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2002
    ....
  36. MULTIDICIPLINARY FUNCTIONAL IMAGING OF CANCER
    Zaver Bhujwalla; Fiscal Year: 2002
    ..abstract_text> ..
  37. Cardiac Disease and Regeneration
    Stefanie Dimmeler; Fiscal Year: 2005
    ..As aging is a major risk factor for cardiovascular disease a special session will focus on the molecular determinants of aging and its role in cardiac diseases. ..
  38. FACTORS INFLUENCING STEM CELL AND PLATELET PRODUCTION
    Malcolm Moore; Fiscal Year: 2002
    ..e., adult populations acquiring features of neonatal cells, or whether there is a tendency for "immortalized" cells to undergo neoplastic transformation. ..
  39. Cyclic Follicle Function and Angiogenesis
    Ralf Zimmermann; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  40. HYPOXIA AND HEPATIC FIBROGENESIS
    Victor Ankoma Sey; Fiscal Year: 2002
    ..abstract_text> ..
  41. BLADDER CANCER BIOMARKERS GUIDES TO SURGERY AND THERAPY
    Robert Hurst; Fiscal Year: 2003
    ..The results of this study should generate biomarker profiles that are based in basic, mechanistic understanding of metastasis that can subsequently be tested in controlled clinical studies. ..
  42. FOUR DIMENSIONAL IMAGING OF THE IMMUNE RESPONSE IN VIVO
    James T Rosenbaum; Fiscal Year: 2010
    ..These studies should result in a fundamental improvement in the understanding of how T cells behave within a site of inflammation. ..
  43. Humanin as a novel cardioprotective and angiogenic factor
    BALVIN CHUA; Fiscal Year: 2007
    ..g. coronary bypass). Finally, humanin has the potential to promote new blood vessel formation in damaged myocardium. [unreadable] [unreadable] [unreadable]..
  44. INITIATION AND REGULATION OF BLOOD COAGULATION
    VIJAYA MOHAN RAO LELLA; Fiscal Year: 2010
    ..abstract_text> ..
  45. Identifying Vegf target genes during artery development
    Nathan Lawson; Fiscal Year: 2005
    ....
  46. Endotoxin-induced Uveitis Revisited
    James T Rosenbaum; Fiscal Year: 2010
    ..Future studies can buil d on these observations to test anti-inflammtory molecules induced by endotoxin as these molecules are potentially useful in the treatment of uveitis and other inflammations. ..
  47. Nanoparticle delivery of antiangiogenic genes
    Gerard Lutty; Fiscal Year: 2003
    ..The goal of this proposal is to deliver genes for endogenous antiangiogenic agents to sites of ocular neovascularization. ..
  48. IMMUNOMODULATION OF RETROVIRAL CARDIOPATHOLOGY
    RONALD WATSON; Fiscal Year: 2001
    ..The treatments that found to prevent cytokine dysregulation and cardiotoxicitiy in retrovirally infected mice will then be applicable to reducing heart disease in HIV infected patients (End of Abstract) ..
  49. Thrombospondin-1 in prostate development and neoplasia
    Susan Crawford; Fiscal Year: 2004
    ..Results from these experiments should establish the function of TSP-1 in prostatic growth regulation and determine how TSP-1 may be useful as a prognostic indicator or as a treatment for prostatic diseases. ..
  50. Anterior Uveal Dendritic Cells
    James Rosenbaum; Fiscal Year: 2004
    ..These studies will clarify the function of the immune system within the eye and may suggest novel therapeutic approaches in the treatment of uveitis. ..
  51. Therapy of thrombocytopenic disorders by chemokines
    Shahin Rafii; Fiscal Year: 2007
    ..being evaluated in phase I clinical trials, would provide the platform for assessing the role of these agents in amelioration and rapid restoration of thrombocytopenia Induced by chemotherapy and irradiation [unreadable] [unreadable]..
  52. Polymer Carrier for Ischemia-Inducible Gene Therapy
    David Bull; Fiscal Year: 2007
    ..abstract_text> ..
  53. Micro-Thickness Collagen Membranes in Tissue Engineering
    Robert Vernon; Fiscal Year: 2007
    ..Moreover, data from this work will serve as a foundation for further development of TEBVs. Accordingly, this application is well suited to the purpose of the R21 mechanism. [unreadable] [unreadable] [unreadable]..
  54. P53 Based Vaccine for Small Cell Lung Cancer
    Dmitry Gabrilovich; Fiscal Year: 2007
    ..Specific Aim 2. Determine the immune modifying effect of immunization and chemotherapy on p53-specific immunity. [unreadable] [unreadable] [unreadable]..
  55. Lymphoid Transformation with Human Herpesvirus 8 K1
    Felipe Samaniego; Fiscal Year: 2005
    ..By carrying out the plans in this application, the PI will show how a viral gene participates in inducing lymphoma and offer insights into therapy. ..
  56. SUPPRESSION OF VASCULAR GROWTH
    Luisa Iruela Arispe; Fiscal Year: 2008
    ..We anticipate that results from these experiments will shed light into the biology of tumor growth and angiogenesis. ..
  57. CARDIOVASCULAR SURGERY RESEARCH TRAINING GRANT
    Frank Sellke; Fiscal Year: 2008
    ..It is anticipated that this program in cardiovascular surgery research training will help the specialty continue to train outstanding academic surgeons in times of financial, clinical, and educational uncertainty. ..
  58. Subconjunctival Route to Prolong Corticosteroid Delivery
    Uday Kompella; Fiscal Year: 2005
    ..Based on this study, the PI will submit an RO-l proposal to assess subconjunctival budesonide-PLGA particles for the therapy of posterior segment disorders associated with inflammation and/or VEGF elevation. ..
  59. ADENOVIRAL VECTORS FOR DELIVERY OF ANGIOGENIC CYTOKINES
    HAROLD DVORAK; Fiscal Year: 2008
    ..Aim 2. Elucidate the mechanisms by which mother vessels evolve into daughter vessels. Aim 3. Generate normal blood vessels with mixtures of primary and secondary cytokines. ..
  60. Epigallocatechin gallate, Prostate cancer & Angiogenesis
    Myoung Kim; Fiscal Year: 2004
    ..abstract_text> ..
  61. Treatment of lung cancer
    Derick Lau; Fiscal Year: 2008
    ..The long-term goal is to develop these peptide ligands as molecularly targeted therapy for lung cancer. 4. To recruit and train hematology and oncology specialists in clinical research of cancer therapy. ..
  62. CELL SUBPOPULATIONS IN THE PRIMATE CORPUS LUTEUM
    Richard Stouffer; Fiscal Year: 2001
    ..Overall, the proposed research may have relevance to an understanding of certain ovarian disorders such as ovarian hyperstimulation syndrome and luteal phase defects where microvasculature growth may be disrupted. ..
  63. Effects of the Angiopoietins on Tie 2 Downregulation
    Christopher Kontos; Fiscal Year: 2005
    ..abstract_text> ..
  64. Systems Biology of Angiogenesis: from Molecules to Therapy
    BRIAN ANNEX; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  65. Conference on Angiogenesis in Cancer and Other Diseases
    Rakesh Jain; Fiscal Year: 2002
    ..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..